Novel neurotrophic factors
OwnerTeit E. Johansen, Dinah Wen-Yee Sahinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
Claims54
A truncated neublastin polypeptide, wherein the amino terminus of said truncated neublastin polypeptide lacks one or more amino-terminal amino acids of a mature neublastin polypeptide.
A polypeptide comprising the amino acid sequence of a truncated neublastin polypeptide, wherein the amino acid sequence of said truncated neublastin polypeptide is less than 113 amino acids in length and includes an amino acid sequence at least 70% homologous to amino acids 122-220 of SEQ ID NO:9.
A pharmaceutical composition comprising a truncated neublastin polypeptide and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a nucleic acid encoding a truncated neublastin polypeptide and a pharmaceutically acceptable carrier.
A method of treating a peripheral neuropathy in a mammal, comprising administering a therapeutically effective amount of a truncated neublastin polypeptide to said mammal.
A method of treating neuropathic pain in a mammal, comprising administering a therapeutically effective amount of a truncated neublastin polypeptide to said mammal.
A method of treating a peripheral neuropathy in a mammal, the method comprising administering a therapeutically effective amount of a nucleic acid encoding truncated neublastin polypeptide to said mammal.
A kit comprising, in one or more containers, a substance selected from the group consisting of a truncated neublastin polypeptide and a nucleic acid encoding a truncated neublastin polypeptide.
Dependencies are inferred from the claim text.